Menu
Ms. Nursella has over 15 years of broad experience in senior financial and operational positions within public and private biotechnology companies supporting fund raising, licensing, partnerships and M&A transactions with total value exceeding billion USD with global companies.
She has a deep expertise with building and leading finance functions in addition to overseeing and collaborating with other critical business groups to enable growth and realization of value.
Prior to joining ImmPACT Bio, she served as a CFO of Adicet Bio, a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases (NASDAQ: ACET) and General Manager of Adicet Israel.
Ms. Nursella is a former CFO of cCam Biotherapeutics Ltd (acquired by Merck), Keystone Heart Ltd (acquired by Venus Medtech) , RDD Pharma Ltd , OticPharma Ltd, NasVax Ltd (TASE:NSVX), Elutex Ltd (TASE: ELTX).
Ms. Nursella holds the MA Law degree from Bar-Ilan University and BA, Finance and Economics degree from the University of Haifa and she is a Certified Public Accountant.
You are about to leave Immpact Bio's website to an external website.
Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.
You are about to leave Immpact Bio's website to an external website.
Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.
You are about to leave Immpact Bio's website to an external website.
Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.
You are about to leave Immpact Bio's website to an external website.
Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.
ImmPACT Bio is now part of Lyell Immunopharma
If you have a question about a clinical trial, please contact us at info@immpact-bio.com
